CRISPR Unlocks Sweeter Tomatoes Without Yield Loss
Carbon
Nov. 19, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Biomedrex Genetics
Main focus: Next-generation CRISPR-based antiviral therapies
Company stage: Pre-clinical
Diseases (gene editing): HIV-1, influenza, SARS-CoV-2
Genome editing tool: CRISPR
Funding stage: Private
Location: Huddinge, Sweden
Website: https://www.biomedrex.com/index.html
Biomedrex Genetics is a start-up company that develops novel antiviral treatments based on the CRISPR-Cas system. The company aims to treat various infectious diseases, with HIV-1 being the lead viral target. The company is currently conducting pre-clinical testing.
